Whole Cell Assays and Methods
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 13/494,618, filed Jun 12, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,404,915 | Whole Cell Assays and Methods In force · High confidence | Celcuity Inc. | In force | High confidence | ||
| US 10,041,934 | Whole Cell Assays and Methods In force · High confidence | Celcuity Inc. | In force | High confidence | ||
| US 10,976,307 | Whole Cell Assays and Methods In force · High confidence | Celcuity Inc. | In force | High confidence | ||
| Application 13/494,618 | Whole Cell Assays and Methods Abandoned Abandoned Jun 11, 2015 | Celcuity Inc. | Abandoned | Abandoned Jun 11, 2015 | not computed | |
| Application 17/193,891 | Whole Cell Assays and Methods Abandoned Abandoned Aug 8, 2026 | Celcuity Inc. | Abandoned | Abandoned Aug 8, 2026 | not computed |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Celcuity Inc..
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.